Medpace Holdings, Inc. $MEDP Position Increased by Smith Group Asset Management LLC

Smith Group Asset Management LLC raised its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 82,223 shares of the company’s stock after buying an additional 2,529 shares during the quarter. Medpace accounts for 1.7% of Smith Group Asset Management LLC’s portfolio, making the stock its 28th largest position. Smith Group Asset Management LLC owned about 0.29% of Medpace worth $25,807,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the company. Whittier Trust Co. lifted its position in shares of Medpace by 47.3% in the first quarter. Whittier Trust Co. now owns 109 shares of the company’s stock worth $33,000 after purchasing an additional 35 shares in the last quarter. PDS Planning Inc grew its position in Medpace by 1.5% during the second quarter. PDS Planning Inc now owns 2,421 shares of the company’s stock valued at $760,000 after purchasing an additional 35 shares in the last quarter. Benjamin Edwards Inc. grew its position in Medpace by 3.1% during the first quarter. Benjamin Edwards Inc. now owns 1,201 shares of the company’s stock valued at $366,000 after purchasing an additional 36 shares in the last quarter. Geneos Wealth Management Inc. grew its position in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares in the last quarter. Finally, Assetmark Inc. grew its position in Medpace by 24.9% during the first quarter. Assetmark Inc. now owns 216 shares of the company’s stock valued at $66,000 after purchasing an additional 43 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Medpace in a research report on Wednesday, October 8th. Truist Financial increased their price objective on Medpace from $298.00 to $436.00 and gave the stock a “hold” rating in a report on Wednesday, July 23rd. Cowen downgraded Medpace from a “buy” rating to a “sell” rating in a report on Wednesday, July 23rd. Barclays increased their price objective on Medpace from $300.00 to $450.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 23rd. Finally, Rothschild Redb downgraded Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. Two investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and an average target price of $430.60.

Medpace Stock Up 9.1%

Shares of MEDP stock opened at $596.61 on Friday. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $625.00. The business’s 50 day moving average is $500.19 and its two-hundred day moving average is $389.01. The company has a market cap of $16.76 billion, a PE ratio of 41.72, a price-to-earnings-growth ratio of 3.39 and a beta of 1.40.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating the consensus estimate of $3.50 by $0.36. Medpace had a return on equity of 81.62% and a net margin of 18.36%.The company had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. During the same quarter last year, the company posted $3.01 earnings per share. The company’s revenue for the quarter was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, equities analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Activity at Medpace

In other news, CEO August J. Troendle sold 36,196 shares of the firm’s stock in a transaction on Friday, August 29th. The shares were sold at an average price of $475.90, for a total value of $17,225,676.40. Following the sale, the chief executive officer owned 925,799 shares in the company, valued at approximately $440,587,744.10. This trade represents a 3.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Cornelius P. Mccarthy III sold 1,662 shares of the firm’s stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $465.04, for a total transaction of $772,896.48. Following the completion of the sale, the director owned 10,197 shares in the company, valued at approximately $4,742,012.88. The trade was a 14.01% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 107,465 shares of company stock worth $49,720,216. Insiders own 20.30% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.